PL 17871/0208 UKPAR TABLE OF CONTENTS
|
|
- Osborne Thomas
- 1 years ago
- Views:
Transcription
1 Fultium-D 3 3,200 IU Capsules PL 17871/0208 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 11 Summary of Product Characteristics Page 12 Patient Information Leaflet Page 13 Labelling Page 14 1
2 LAY SUMMARY Fultium-D 3 3,200 IU Capsules (colecalciferol) This is a summary of the Public Assessment Report (PAR) for Fultium-D 3 3,200 IU Capsules (PL 17871/0208). It explains how Fultium-D 3 3,200 IU Capsules were assessed and their authorisation recommended, as well as their conditions of use. It is not intended to provide practical advice on how to use Fultium-D 3 3,200 IU Capsules. For practical information about using Fultium-D 3 3,200 IU Capsules, patients should read the package leaflet or contact their doctor or pharmacist. What are Fultium-D 3 3,200 IU Capsules and what are they used for? Fultium-D 3 3,200 IU Capsules contain the active substance colecalciferol (equivalent to vitamin D3). Fultium-D 3 3,200 IU Capsules are used to treat vitamin D deficiency. How are Fultium-D 3 3,200 IU Capsules used? Fultium-D 3 3,200 IU Capsules are taken by mouth. A single capsule should be swallowed whole (not chewed) with water. The recommended dose for adults and the elderly is 1 capsule (3,200 IU) daily for up to 12 weeks dependent upon the severity of the disease and the patient s response to treatment. Fultium-D 3 3,200 IU Capsules should not be used in children under 12 years. Fultium-D 3 3,200 IU Capsules can only be obtained on prescription from a doctor. For further information on how Fultium-D 3 3,200 IU Capsules are used, please refer to the Summary of Product Characteristics and the Patient Information Leaflet available on the MHRA website. How do Fultium-D 3 3,200 IU Capsules work? Fultium-D3 3,200 IU Capsules are vitamin products containing colecalciferol (equivalent to vitamin D3). Vitamin D3 acts to maintain normal concentrations of calcium and phosphate in plasma by facilitating their absorption from the small intestine, enhancing their mobilisation from bone and decreasing their excretion by the kidney. How have Fultium-D 3 3,200 IU Capsules been studied? As colecalciferol is a well-known substance and has a well-established use, the applicant (Jenson Pharmaceutical Services Ltd) presented data from the scientific literature. The literature provided confirmed the efficacy and safety of colecalciferol for the treatment of vitamin D deficiency. What are the Benefits and risks of Fultium-D 3 3,200 IU Capsules? Colecalciferol is a well-known active ingredient. Colecalciferol-containing products have been available in the European Union for many years and have an established favourable benefit-risk profile. For information about side effects that may occur with taking Fultium-D 3 3,200 IU Capsules, please refer to the package leaflet or the Summary of Product Characteristics available on the MHRA website. Why are Fultium-D 3 3,200 IU Capsules approved? The use of Fultium-D 3 3,200 IU Capsules for the approved indications is well-established. Literature data have been submitted to support this application. No new or unexpected safety concerns arose from this application. It was, therefore, considered that the benefits of Fultium-D 3 3,200 IU Capsules outweigh the risks and the grant of a Marketing Authorisation was recommended. 2
3 What measures are being taken to ensure the safe and effective use of Fultium-D3 3,200 IU Capsules? A Risk Management Plan has been developed to ensure that Fultium-D 3 3,200 IU Capsules are used as safely as possible. Based on this plan, safety information has been included in the Summary of Product Characteristics and the package leaflet for Fultium-D 3 3,200 IU Capsules, including the appropriate precautions to be followed by healthcare professionals and patients. Other information about Fultium-D 3 3,200 IU Capsules A Marketing Authorisation was granted in the UK on 17 th April The full PAR for Fultium-D 3 3,200 IU Capsules follows this summary. For more information about treatment with Fultium-D 3 3,200 IU Capsules, read the package leaflet, or contact your doctor or pharmacist. This summary was last updated in June
4 Fultium-D 3 3,200 IU Capsules PL 17871/0208 SCIENTIFIC DISCUSSION TABLE OF CONTENTS Introduction Page 5 Pharmaceutical assessment Page 6 Non-clinical assessment Page 8 Clinical assessment Page 9 Overall conclusion and benefit/risk assessment Page 10 4
5 INTRODUCTION Based on the review of the data on quality, safety and efficacy, the Medicines and Healthcare products Regulatory Agency (MHRA) granted Jenson Pharmaceutical Services Ltd a Marketing Authorisation for the medicinal product Fultium-D 3 3,200 IU Capsules (PL 17871/0208) on 17 th April The product is a prescription-only medicine (POM) indicated for the treatment of vitamin D deficiency. This is a line extension application submitted under Article 10a, well-established use, of Directive 2001/83/EC, as amended, and concerns a new strength of the currently licensed product, Fultium-D IU Capsules (PL 17871/0151). In its biologically active form vitamin D 3 stimulates intestinal calcium absorption, incorporation of calcium into the osteoid, and release of calcium from bone tissue. In the small intestine it promotes rapid and delayed calcium uptake. The passive and active transport of phosphate is also stimulated. In the kidney, it inhibits the excretion of calcium and phosphate by promoting tubular resorption. The production of parathyroid hormone (PTH) in the parathyroids is inhibited directly by the biologically active form of vitamin D 3. PTH secretion is inhibited additionally by the increased calcium uptake in the small intestine under the influence of biologically active vitamin D 3. No new non-clinical or clinical studies were necessary for this application, which is acceptable given that this is a bibliographic application for a product containing an active of well-established use. Bioequivalence studies are not necessary to support this application. The MHRA has been assured that acceptable standards of Good Manufacturing Practice (GMP) are in place for this product type at all sites responsible for the manufacturing and assembly of this product. Evidence of compliance with GMP has been provided for the named manufacturing and assembly sites. 5
6 PHARMACEUTICAL ASSESSMENT ACTIVE SUBSTANCE INN: Colecalciferol Chemical name: (5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3β-ol Structure: Molecular formula: Molecular weight: Appearance: Solubility C 27 H 44 O g/mol White or almost white crystalline powder Practically insoluble in water, freely soluble in ethanol (96 per cent) and soluble in trimethylpentane and in fatty oils. Colecalciferol is the subject of a European Pharmacopoeia monograph. All aspects of the manufacture and control of the active substance colecalciferol are covered by a European Directorate for the Quality of Medicines and Healthcare (EDQM) Certificate of Suitability. DRUG PRODUCT Other Ingredients Other ingredients consist of the pharmaceutical excipients arachis Oil (peanut oil), butylated hydroxytoluene (BHT) (E321) making up the capsule content. The capsule shell is composed of glycerol (E422), chlorophyllin copper complex sodium (E141), gelatin (E441) and purified water. Appropriate justification for the inclusion of each excipient has been provided. All excipients comply with their respective European Pharmacopoeia monographs with the exception of chlorophyllin copper complex sodium (E14) which complies with the United States Pharmacopeia. The only excipient used that contains material of animal or human origin is gelatin. Satisfactory documentation has been provided by the gelatin suppliers stating that the gelatin they provide complies with the criteria described in the current version of the monograph Products with risk of transmitting agents of animal spongiform encephalopathies. Confirmation has also been given that the glycerol used in the capsules is of vegetable origin. Satisfactory Certificates of Analysis have been provided for all excipients showing compliance with the proposed specifications. Pharmaceutical Development The objective of the development programme was to formulate a safe, efficacious, stable line extension presentation containing 3,200 IU of colecalciferol. 6
7 Suitable pharmaceutical development data have been provided for this application. Manufacturing Process A satisfactory batch formula has been provided for the manufacture of the product, along with an appropriate account of the manufacturing process. The manufacturing process has been validated and has shown satisfactory results. Process validation data on commercial batches have been provided. The results are satisfactory. Control of Finished Product The finished product specification is satisfactory. The test methods have been described and have been adequately validated, as appropriate. Batch data have been provided that comply with the release specification. Certificates of Analysis have been provided for any working standards used. Container Closure System The product is packed in an opaque, white polyvinylchloride (PVC), polyvinylidenechloride (PVDC) blister tray with aluminium foil. The pack sizes are 7, 10, 14, 20, 28, 30, 56, 60, 84 and 90 capsules. Not all pack sizes may be marketed. Satisfactory specifications and Certificates of Analysis have been provided for all packaging components. All primary packaging complies with the current European regulations concerning materials in contact with food. Stability Finished product stability studies were performed in accordance with current guidelines on batches of finished product packed in the packaging proposed for marketing. Based on the results, a shelf-life of 12 months with storage conditions Do not store above 30 C and Store blister foil in original container in order to protect from light have been set. These are satisfactory. Suitable post approval stability commitments have been provided to continue stability studies on batches of the finished product. Summary of Product Characteristics (SmPC), Patient Information Leaflet (PIL) and Labelling The SmPC, PIL and labelling are satisfactory from a pharmaceutical perspective. User testing of the package leaflet has been accepted, based on a bridging report provided by the applicant making reference to the user-testing of the PIL for Fultium-D IU Capsules (PL 17871/0151). The products are from the same therapeutic class and have similar indications. A critical analysis demonstrated that the key messages for safe and effective use for both leaflets were similar. The justification on the rationale for bridging is accepted. Marketing Authorisation Application (MAA) Form The MAA form is satisfactory from a pharmaceutical perspective. Expert Report (Quality Overall Summary) The quality overall summary is written by an appropriately qualified person and is a suitable summary of the pharmaceutical aspects of the dossier. Conclusion The grant of a Marketing Authorisation is recommended. 7
8 NON-CLINICAL ASSESSMENT As the pharmacodynamic, pharmacokinetic and toxicological properties of colecalciferol are well-known, no further non-clinical studies are required and none have been provided. The applicant s non-clinical overview has been written by an appropriately qualified person and is satisfactory, providing an appropriate review of the relevant non-clinical pharmacology, pharmacokinetics and toxicology. The Marketing Authorisation holder has provided adequate justification for not submitting an Environmental Risk Assessment (ERA). This is acceptable as vitamins are unlikely to result in significant risk to the environment. There are no objections to the approval of this product from a non-clinical point of view. 8
9 CLINICAL ASSESSMENT CLINICAL PHARMACOLOGY No new clinical pharmacology data have been submitted and none are required for applications of this type. The clinical pharmacology of colecalciferol is well-known. EFFICACY No new efficacy data have been submitted and none are required for applications of this type. The clinical efficacy of colecalciferol is well-established. Efficacy is adequately reviewed in the clinical overview. SAFETY No new safety data were supplied or required for this bibliographic application. Safety is adequately reviewed in the clinical overview. The safety profile of colecalciferol is well-known. CLINICAL EXPERT REPORT (CLINICAL OVERVIEW) The clinical overview is written by an appropriately qualified physician and is a suitable summary of the clinical aspects of the dossier. PHARMACOVIGILANCE SYSTEM AND RISK MANAGEMENT PLAN The Pharmacovigilance System, as described by the applicant, fulfils the requirements and provides adequate evidence that the applicant has the services of a qualified person responsible for pharmacovigilance, and has the necessary means for the notification of any adverse reaction suspected of occurring either in the Community or in a third country. A satisfactory Risk Management Plan has been provided. SUMMARY OF PRODUCT CHARACTERISTICS (SmPC), PATIENT INFORMATION LEAFLET (PIL) AND LABELLING The SmPC, PIL and labelling are acceptable from a clinical perspective. The PIL is consistent with the details in the SmPC and in line with the current guidance. The labelling is in line with the current guidance. MAA FORM This is satisfactory. CONCLUSION The grant of a Marketing Authorisation is recommended. 9
10 OVERALL CONCLUSION AND BENEFIT/RISK ASSESSMENT QUALITY The important quality characteristics of Fultium-D 3 3,200 IU Capsules are well-defined and controlled. The specifications and batch analytical results indicate consistency from batch to batch. There are no outstanding quality issues that would have a negative impact on the benefit/risk balance. NON-CLINICAL No new non-clinical data were submitted. As the pharmacokinetics, pharmacodynamics and toxicology of colecalciferol are well-known, no additional data were required. CLINICAL No new clinical data were submitted and none were required for applications of this type. The published literature supports the efficacy of this product in the proposed indications. The efficacy of colecalciferol is well-known. The presented evidence for well-established use of the active substance is sufficient. The safety profile of colecalciferol is well-known. The literature review identified no new or unexpected safety issues or concerns. PRODUCT LITERATURE The SmPC, PIL and labelling are satisfactory and in line with current guidance. BENEFIT/RISK ASSESSMENT The quality of the product is acceptable, and no new non-clinical or clinical concerns have been identified. Extensive clinical experience with colecalciferol is considered to have demonstrated the therapeutic value of the compound. The benefit:risk is, therefore, considered to be positive. 10
11 Fultium-D 3 3,200 IU Capsules PL 17871/0208 STEPS TAKEN FOR ASSESSMENT 1 The MHRA received the Marketing Authorisation application on 19 th July Following standard checks and communication with the applicant the MHRA considered the application valid on 21 st October Following assessment of the application the MHRA requested further information on 10 th December 2013, 23 rd December 2013, 18 th February 2014, 3 rd March 2014 and 5 th March The applicant responded to the MHRA s requests, providing further information on 3 rd January 2014, 26 th February 2014, 11 th March 2014 and 19 th March The application was determined on 17 th April
12 SUMMARY OF PRODUCT CHARACTERISTICS In accordance with Directive 2010/84/EU, the Summaries of Product Characteristics (SmPCs) for products granted Marketing Authorisations at a national level are available on the MHRA website. 12
13 PATIENT INFORMATION LEAFLET In accordance with Directive 2010/84/EU, the Patient Information Leaflets (PILs) for products granted Marketing Authorisations at a national level are available on the MHRA website. 13
14 LABELLING 14
15 15
InVita D3 25,000 IU oral solution PL 24837/0039
InVita D3 25,000 IU oral solution PL 24837/0039 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 5 Steps taken for assessment Page 12 Summary of Product Characteristics Page 13 Patient
Paracetamol 1000 mg Effervescent Tablets PL 31388/0005
Paracetamol 1000 mg Effervescent Tablets PL 31388/0005 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 12 Summary of Product Characteristics Page
Public Assessment Report
Public Assessment Report Sodium Chloride 1 mmol/ml Oral Solution (sodium chloride) UK Licence No: PL 20346/0008 Viridian Pharma Ltd LAY SUMMARY Sodium Chloride 1 mmol/ml Oral Solution (sodium chloride)
DEXAMETHASONE 0.5 MG TABLETS PL 17507/0052 TABLE OF CONTENTS
DEXAMETHASONE 0.5 MG TABLETS PL 17507/0052 TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 11 Steps taken after authorisation summary Page 12 Summary of
Public Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure Thorens 10 000 I.U. /ml oral drops, solution Thorens 25 000 I.U. /2.5 ml oral solution Deltius 10 000 I.U. /ml oral drops, solution Deltius 25 000 I.U.
Sterilised Water for Injections PL 08801/0057 UKPAR
Sterilised Water for Injections PL 08801/0057 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 11 Summary of Product Characteristics Page 12 Patient
Public Assessment Report. UK National Procedure. (colecalciferol) PL 16508/0047 PL 16508/0048. ProStrakan Ltd.
Public Assessment Report UK National Procedure STEXEROL-D 3 1,000 IU FILM-COATED TABLETS STEXEROL-D 3 25,000 IU FILM-COATED TABLETS (colecalciferol) PL 16508/0047 PL 16508/0048 ProStrakan Ltd. 1 LAY SUMMARY
PAROXETINE 20 MG TABLETS PAROXETINE 30 MG TABLETS PL 40378/ UKPAR TABLE OF CONTENTS
PAROXETINE 20 MG TABLETS PAROXETINE 30 MG TABLETS PL 40378/0101-0102 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 4 Steps Taken for Assessment Page 11 Summary of Product Characteristics
Public Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure Olopatadine Zentiva 1 mg/ml eye drops, solution (olopatadine hydrochloride) Procedure No: UK Licence No: PL 17780/0568 Winthrop Pharmaceuticals UK Limited
Donepezil hydrochloride 10 mg film-coated tablets PL 19156/0130
Donepezil hydrochloride 10 mg film-coated tablets PL 19156/0130 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 4 Steps Taken for Assessment Page 12 Summary of Product Characteristics
Lacidipine 2 mg Film-Coated Tablets PL 08553/0502. Lacidipine 4 mg Film-Coated Tablets PL 08553/0503. UK Public Assessment Report
Lacidipine 2 mg Film-Coated Tablets PL 08553/0502 Lacidipine 4 mg Film-Coated Tablets PL 08553/0503 UK Public Assessment Report TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken
HYDROCORTISONE 10 MG TABLETS
HYDROCORTISONE 10 MG TABLETS (Hydrocortisone) PL 20072/0238 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 12 Steps taken after authorisation summary
Public Assessment Report
Public Assessment Report Decentralised Procedure Zoledronic Acid 4mg/5ml Concentrate for Solution for Infusion Procedure No: UK Licence No: PL 24598/0029 Noridem Enterprises Limited LAY SUMMARY On 25 January
Memantine hydrochloride 20 mg film-coated tablets PL 17907/0291
Memantine hydrochloride 20 mg film-coated tablets PL 17907/0291 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 5 Steps Taken for Assessment Page 13 Summary of Product Characteristics
Ibuprofen 200mg Soft Capsules PL 03105/0105 UKPAR
Ibuprofen 200mg Soft Capsules PL 03105/0105 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 13 Summary of Product Characteristics Page 14 Patient
STREPSILS BLACKCURRANT FLAVOUR LOZENGES STREPSILS DRY & SORE THROAT BLACKCURRANT FLAVOUR LOZENGES
STREPSILS BLACKCURRANT FLAVOUR LOZENGES STREPSILS DRY & SORE THROAT BLACKCURRANT FLAVOUR LOZENGES (amylmetacresol, 2,4-dichlorobenzyl alcohol, ascorbic acid and sodium ascorbate) PL 00063/0692 UKPAR TABLE
Fexofenadine Hydrochloride 120 mg Film-coated Tablets Fexofenadine Hydrochloride 180 mg Film-coated Tablets PL 36390/0053-4 UKPAR TABLE OF CONTENTS
Fexofenadine Hydrochloride 120 mg Film-coated Tablets Fexofenadine Hydrochloride 180 mg Film-coated Tablets PL 36390/0053-4 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 5 Steps
EMCREM CREAM (White soft paraffin 15.0% w/w, Liquid paraffin 6.0% w/w) PL 19876/0013
EMCREM CREAM (White soft paraffin 15.0% w/w, Liquid paraffin 6.0% w/w) PL 19876/0013 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Steps taken
TRAMADOL HYDROCHLORIDE AND PARACETAMOL 37.5 MG/325 MG FILM-COATED TABLETS (tramadol hydrochloride and paracetamol ) PL 30684/0222 UKPAR
TRAMADOL HYDROCHLORIDE AND PARACETAMOL 37.5 MG/325 MG FILM-COATED TABLETS (tramadol hydrochloride and paracetamol ) PL 30684/0222 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4
Levonorgestrel/Ethinylestradiol 150/30 Microgram Coated Tablets PL 20117/0044
Levonorgestrel/Ethinylestradiol 150/30 Microgram Coated Tablets PL 20117/0044 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Summary of Product
Public Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure TELMISARTAN DR REDDY S 20 MG TABLETS TELMISARTAN DR REDDY S 40 MG TABLETS TELMISARTAN DR REDDY S 80 MG TABLETS (telmisartan) Procedure No: UK/H/5034/001-003/DC
Public Assessment Report UKPAR. Fluoride 2800 ppm Toothpaste Fluoride 5000 ppm Toothpaste. (Sodium fluoride) UK Licence No: PL 20117/
Public Assessment Report UKPAR Fluoride 2800 ppm Toothpaste Fluoride 5000 ppm Toothpaste (Sodium fluoride) UK Licence No: PL 20117/0239-0240 Morningside Healthcare Limited 1 LAY SUMMARY Fluoride 2800 ppm
MACROGOL COMPOUND ORAL POWDER (sodium chloride, sodium hydrogen carbonate, potassium chloride, macrogol 3350) PL 33579/0001 UKPAR TABLE OF CONTENTS
MACROGOL COMPOUND ORAL POWDER (sodium chloride, sodium hydrogen carbonate, potassium chloride, macrogol 3350) PL 33579/0001 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps
ANASTROZOLE 1 MG FILM-COATED TABLETS. (Anastrozole) PL 40378/0123 UKPAR TABLE OF CONTENTS
ANASTROZOLE 1 MG FILM-COATED TABLETS (Anastrozole) PL 40378/0123 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Summary of Product Characteristics
Aciclovir 200mg Tablets Aciclovir 400mg Tablets Aciclovir 800mg Tablets PL 29831/0517 PL 29831/0518 PL 29831/0519 UKPAR
Aciclovir 200mg Tablets Aciclovir 400mg Tablets Aciclovir 800mg Tablets PL 29831/0517 PL 29831/0518 PL 29831/0519 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for
Public Assessment Report UKPAR. Levonorgestrel 1.5 mg tablet. (levonorgestrel). UK Licence No: PL 41947/0006. ELC Group s.r.o.
Public Assessment Report UKPAR Levonorgestrel 1.5 mg tablet (levonorgestrel). UK Licence No: PL 41947/0006 ELC Group s.r.o. 1 LAY SUMMARY Levonorgestrel 1.5 mg tablet (Levonorgestrel, tablet, 1.5 mg) This
Nicotine 1 mg Compressed Lozenge Nicotine 2 mg Compressed Lozenge PL 00030/0463-0468
Nicotine 1 mg Compressed Lozenge Nicotine 2 mg Compressed Lozenge PL 00030/0463-0468 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 5 Steps Taken for Assessment Page 13 Summary of
Public Assessment Report UKPAR. Galpharm Nicotine Replace 2 mg and 4 mg Gum. (Nicotine resinate) UK Licence No: PL 12063/
Public Assessment Report UKPAR Galpharm Nicotine Replace 2 mg and 4 mg Gum (Nicotine resinate) UK Licence No: PL 12063/0133-0134 Wrafton Laboratories Limited 1 LAY SUMMARY Galpharm Nicotine Replace 2 mg
Omeprazole 20 mg gastro-resistant tablets PL 14017/0277
Omeprazole 20 mg gastro-resistant tablets PL 14017/0277 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 4 Steps Taken for Assessment Page 11 Steps Taken After Initial Authorisation
Public Assessment Report UKPAR. Nurofen Joint & Back Pain Relief 5% Gel Nurofen Muscular Pain Relief Gel Pharmacy Only. Ibuprofen
Public Assessment Report UKPAR Nurofen Joint & Back Pain Relief 5% Gel Ibuprofen UK Licence No: Reckitt Benckiser Healthcare (UK) Limited 1 LAY SUMMARY Nurofen Joint & Back Pain Relief 5% Gel (ibuprofen)
Public Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure Amlodipine Pfizer 5 mg tablets Amlodipine Pfizer 10 mg tablets Amlodipine Pfizer 5 mg hard capsules Amlodipine Pfizer 10 mg hard capsules Procedure No:
Public Assessment Report. Scientific discussion. Calcium and Vitamine D3 Alpex 1000 mg/880 IE, effervescent granules
Public Assessment Report Scientific discussion Calcium and Vitamine D3 Alpex 1000 mg/880 IE, effervescent granules (calcium carbonate and cholecalciferol) NL License RVG: 111783 Date: 12 March 2015 This
RILUZOLE LUPIN 50 MG FILM-COATED TABLETS PL 35507/0120 UKPAR TABLE OF CONTENTS
RILUZOLE LUPIN 50 MG FILM-COATED TABLETS PL 35507/0120 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 9 Steps taken after authorisation summary
Public Assessment Report. Decentralised Procedure PARACETAMOL 1000 MG TABLETS. Procedure No: UK/H/5004/01/DC. UK Licence No: PL 18866/0060
Public Assessment Report Decentralised Procedure PARACETAMOL 1000 MG TABLETS Procedure No: UK Licence No: PL 18866/0060 Rockspring Healthcare Ltd LAY SUMMARY On 17 January 2013 the Medicines and Healthcare
Public Assessment Report UKPAR. Clobetasol Propionate 0.05% w/w Cream Clobetasol Propionate 0.05% w/w Ointment. (Clobetasol propionate).
Public Assessment Report UKPAR Clobetasol Propionate 0.05% w/w Cream Clobetasol Propionate 0.05% w/w Ointment (Clobetasol propionate). UK Licence No: PL 17507/0235-0236 Auden Mckenzie (Pharma Division)
Public Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure FOSFOMYCIN 3G GRANULES FOR ORAL SOLUTION Procedure No: UK Licence No: PL 31513/0007 Temapharm Sp. z.o.o. LAY SUMMARY On 17 April 2013, Czech Republic, Estonia,
(paracetamol and caffeine) PL 00071/0659
Paracetamol and Caffeine 500 mg/65 mg Tablets (paracetamol and caffeine) PL 00071/0659 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 14 Steps taken
MIGRAINE RELIEF 342 MG FILM-COATED TABLETS PL 20154/0030 UKPAR TABLE OF CONTENTS
MIGRAINE RELIEF 342 MG FILM-COATED TABLETS PL 20154/0030 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 13 Steps taken after authorisation summary
LEMSIP MAX DAY & NIGHT COLD & FLU RELIEF CAPSULES. (paracetamol, caffeine and phenylephrine hydrochloride)
LEMSIP MAX DAY & NIGHT COLD & FLU RELIEF CAPSULES (paracetamol, caffeine and phenylephrine hydrochloride) PL 00063/0529 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 5 Summary of
Public Assessment Report. Decentralised Procedure. Cefuroxime 250mg and 500mg film-coated tablets. Cefuroxime 500mg film-coated tablets
Public Assessment Report Decentralised Procedure Cefuroxime 250mg film-coated tablets Cefuroxime 500mg film-coated tablets Procedure No: UK Licence No: PL 35646/0020-0021 Alkem Pharma GmbH 1 LAY SUMMARY
Montelukast 10mg film-coated tablets PL 17907/0474
Montelukast 10mg film-coated tablets PL 17907/0474 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 4 Steps Taken for Assessment Page 11 Steps Taken After Initial Authorisation Page
Summary Public Assessment Report. Generics. Escitalopram Ratiopharm PT/H/0846/01-04/DC. Date:
Summary Public Assessment Report Generics 5 mg, 10 mg, 15 mg, 20 mg, Orodisperdible tablets (escitalopram, oxalate) PT/H/0846/001-004/DC Date: 07-11-2014 1/7 Summary Public Assessment Report Generics Escitalopram,
Public Assessment Report. Decentralised Procedure. Sildenafil Dr. Reddy s 25, 50 and 100mg Filmcoated. Sildenafil citrate UK/H/4855/001-3/DC
Public Assessment Report Decentralised Procedure Sildenafil Dr. Reddy s 25, 50 and 100mg Filmcoated Sildenafil citrate UK licence no: PL 08553/0468-70 DR Reddy s Laboratories (UK) Limited 1 LAY SUMMARY
Public Assessment Report. Decentralised Procedure. Cefadroxil 250 mg/5 ml granules for oral. (Cefadroxil monohydrate)
Public Assessment Report Decentralised Procedure Cefadroxil 250 mg/5 ml granules for oral suspension (Cefadroxil monohydrate) UK licence no: PL 34088/0033 Alkaloid-INT d.o.o. 1 Cefadroxil 250 mg/5 ml granules
Beclometasone Dipropionate 50 micrograms per spray Aqueous Nasal Spray PL 16431/0178
Beclometasone Dipropionate 50 micrograms per spray Aqueous Nasal Spray PL 16431/0178 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific Discussion Page 5 Steps Taken for Assessment Page 11 Steps Taken
Ascorbic Acid 50 mg Tablets. Ascorbic Acid 100 mg Tablets. Ascorbic Acid 200 mg Tablets. Ascorbic Acid 500 mg Tablets PL 20416/0286 PL 20416/0287
Ascorbic Acid 50 mg Tablets Ascorbic Acid 100 mg Tablets Ascorbic Acid 200 mg Tablets Ascorbic Acid 500 mg Tablets PL 20416/0286 PL 20416/0287 PL 20416/0288 PL 20416/0289 UKPAR TABLE OF CONTENTS Lay Summary
Urostemol capsules THR 02855/0239
Urostemol capsules THR 02855/0239 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 12 Steps taken after initial registration Page 13 Summary of Product
CETIRIZINE DIHYDROCHLORIDE 10MG FILM-COATED TABLETS PL 40378/0140-1 UKPAR TABLE OF CONTENTS
CETIRIZINE DIHYDROCHLORIDE 10MG FILM-COATED TABLETS PL 40378/0140-1 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 8 Steps taken after authorisation
Public Assessment Report. Decentralised Procedure. Pemetrexed 25 mg/ml Concentrate for Solution for Infusion. (pemetrexed ditrometamol)
Public Assessment Report Decentralised Procedure Pemetrexed 25 mg/ml Concentrate for Solution for Infusion (pemetrexed ditrometamol) Procedure No: UK Licence No: PL 24668/0187 Caduceus Pharma Ltd 1 LAY
Public Assessment Report UKPAR
Public Assessment Report UKPAR Amitriptyline 10 mg film-coated tablets Amitriptyline 25 mg film-coated tablets Amitriptyline 50 mg film-coated tablets (Amitriptyline hydrochloride) UK Licence No: PL 17907/0131-133
Public Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure Levetiracetam 250 mg film-coated tablets PL 36390/0168; UK/H/5630/001/DC Levetiracetam 500 mg film-coated tablets PL 36390/0169; UK/H/5630/002/DC Levetiracetam
NUTRYELT, concentrate for solution for infusion
NUTRYELT, concentrate for solution for infusion Public Assessment Report Decentralised Procedure NUTRYELT, concentrate for solution for infusion (zinc gluconate, copper gluconate, manganese gluconate,
Public Assessment Report. UK National Procedure. Perindopril 2 mg Tablets. Perindopril 4 mg Tablets. Perindopril 8 mg Tablets PL 20075/0294-0296
Public Assessment Report UK National Procedure Perindopril 2 mg Tablets Perindopril 4 mg Tablets Perindopril 8 mg Tablets PL 20075/0294-0296 Accord Healthcare Limited 1 LAY SUMMARY This is a summary of
Boots Pharmaceuticals Bruise Relief Arnica cream THR 01175/0398 UKPAR TABLE OF CONTENTS. Lay summary Page 2. Scientific discussion Page 3
Boots Pharmaceuticals Bruise Relief Arnica cream UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 10 Summary of Product Characteristics Page 11 Patient
Public Assessment Report. Scientific discussion. Paracetamol Orifarm 500 mg film-coated tablets. (Paracetamol) DK/H/2271/001/DC.
Public Assessment Report Scientific discussion Paracetamol Orifarm 500 mg film-coated tablets (Paracetamol) DK/H/2271/001/DC 15 October 2014 This module reflects the scientific discussion for the approval
POTASSIUM NITRATE AND SODIUM FLUORIDE 5/0.315% W/W TOOTHPASTE PL 00036/ UKPAR TABLE OF CONTENTS
POTASSIUM NITRATE AND SODIUM FLUORIDE 5/0.315% W/W TOOTHPASTE PL 00036/0307-9 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Summary of Product
Public Assessment Report. (Budesonide) PL 17901/0254. AstraZeneca UK Ltd
Public Assessment Report Rhinocort Hay Fever 64 micrograms, Nasal Spray (Budesonide) PL 17901/0254 AstraZeneca UK Ltd 1 LAY SUMMARY Rhinocort Hay Fever 64 micrograms, Nasal Spray (Budesonide) This is a
Phynova Joint and Muscle Relief Tablets THR 41783/0001 UKPAR
Phynova Joint and Muscle Relief Tablets THR 41783/0001 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 12 Summary of Product Characteristics Page
CANESTEN DUAL ACTION 1% W/W CREAM (PL 00010/0645) UKPAR TABLE OF CONTENTS
CANESTEN DUAL ACTION 1% W/W CREAM (PL 00010/0645) UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 12 Steps taken after authorisation summary Page
Public Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure TEMOZOLOMIDE RELIANCE 20 MG HARD CAPSULES TEMOZOLOMIDE RELIANCE 100 MG HARD CAPSULES TEMOZOLOMIDE RELIANCE 140 MG HARD CAPSULES TEMOZOLOMIDE RELIANCE 180
Summary Public Assessment Report. Generics
Summary Public Assessment Report Generics 875 mg + 125 mg, Film-coated tablets (Amoxicillin Trihydrate + Potassium Clavulanate) Date: 29-12-2014 1/7 Summary Public Assessment Report Generics Amoxicillin
Urostemol Men capsules THR 02855/0240
Urostemol Men capsules THR 02855/0240 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 14 Steps taken after initial registration Page 15 Summary of
Summary Public Assessment Report. Generics. Amoxicilina + Ácido Clavulânico Ranbaxy,
Summary Public Assessment Report Generics Amoxicilina + Ácido Clavulânico Ranbaxy 875 mg + 125 mg, Film-coated tablets (Amoxicillin Trihydrate + Potassium Clavulanate) Date: 29-12-2014 1/7 Summary Public
Decentralised Procedure. Public Assessment Report. Celecoxib-ratiopharm / Celecoxib AbZ 100/200 mg Hartkapseln. (Celecoxib) DE/H/ / /DC
Bundesinstitut für Arzneimittel und Medizinprodukte Decentralised Procedure Public Assessment Report Celecoxib-ratiopharm / Celecoxib AbZ 100/200 mg Hartkapseln (Celecoxib) DE/H/3057-3058/001-002/DC Applicant:
Public Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure PERRIGO PARACETAMOL/GUAIFENESIN/PHENYLEPHRINE HYDROCHLORIDE 500 MG/200 MG/10 MG POWDER FOR ORAL SOLUTION UK Licence No: PL 12063/0118 WRAFTON LABORATORIES
Public Assessment Report. Decentralised Procedure. Mometasone furoate 50 micrograms/actuation nasal spray, suspension
Public Assessment Report Decentralised Procedure Mometasone furoate 50 micrograms/actuation nasal spray, suspension (Mometasone furoate monohydrate) UK/H/5471/01/DC UK licence no: PL 36390/0157 Cipla (EU)
Public Assessment Report
Public Assessment Report Decentralised Procedure Ibuprofen and phenylephrine hydrochloride 200mg/5mg film-coated tablets Procedure No: UK Licence No: PL 17780/0563 Winthrop Pharmaceuticals UK Limited LAY
Health Products Regulatory Authority IPAR IRISH MEDICINES BOARD PUBLIC ASSESSMENT REPORT FOR A MEDICINAL PRODUCT FOR HUMAN USE. Scientific discussion
IPAR IRISH MEDICINES BOARD PUBLIC ASSESSMENT REPORT FOR A MEDICINAL PRODUCT FOR HUMAN USE Scientific discussion Meropenem 500 mg and 1 g, Powder for Solution for Injection or Infusion (Meropenem Trihydrate)
CETRABEN ORIGINAL EMOLLIENT CREAM (PL 06831/0262) UKPAR TABLE OF CONTENTS
CETRABEN ORIGINAL EMOLLIENT CREAM (PL 06831/0262) UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 12 Steps taken after authorisation summary Page
Public Assessment Report
Public Assessment Report Decentralised Procedure Alendronic Acid and Calcium/Cholecalciferol 70+1000mg/880IU Film-coated Tablets+Effervescent Tablets Procedure No: UK Licence No: PL 04416/1162-4 Sandoz
Public Assessment Report. Decentralised Procedure. Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution
Public Assessment Report Decentralised Procedure Ipravent CFC-Free Inhaler 20 micrograms per actuation pressurised inhalation, solution (ipratropium bromide monohydrate) Procedure No: UK Licence No: PL
OMEPRAZOLE 10 MG, 20 MG AND 40 MG GASTRO-RESISTANT HARD CAPSULES. (omeprazole)
OMEPRAZOLE 10 MG, 20 MG AND 40 MG GASTRO-RESISTANT HARD CAPSULES (omeprazole) PL 36884/0001, PL 36884/0002, PL 36884/0003, PL 36884/0004, PL 36884/0005 AND PL 36884/0006 UKPAR TABLE OF CONTENTS Lay Summary
Public Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure Linezolid 2 mg/ml solution for infusion Linezolid 600mg film coated tablets Linezolid 100mg/5ml granules for oral suspension Procedure No: UK Licence No:
Public Assessment Report. Decentralised Procedure. CosmoCol Half 6.9 g, powder for oral solution CosmoCol Paediatric 6.9 g, powder for oral solution
Public Assessment Report Decentralised Procedure CosmoCol Half 6.9 g, powder for oral solution CosmoCol Paediatric 6.9 g, powder for oral solution (Macrogol, sodium chloride, sodium hydrogen carbonate
Public Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure TRIAMCINOLONE HEXACETONIDE 20 MG/ML SUSPENSION FOR INJECTION (triamcinolone hexacetonide) Procedure No: UK Licence No: PL 17509/0061 Intrapharm Laboratories
Dexamethasone 500 microgram Tablets PL 42701/0001 UK PAR
Dexamethasone 500 microgram Tablets PL 42701/0001 UK PAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 14 Steps taken after the initial procedure - summary
GAVISCON ADVANCE MINT CHEWABLE TABLETS PL 00063/0613 UKPAR TABLE OF CONTENTS
GAVISCON ADVANCE MINT CHEWABLE TABLETS PL 00063/0613 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Summary of Product Characteristics Page 12
NEUROTONE THR 00904/0005 UKPAR
NEUROTONE THR 00904/0005 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 10 Summary of Product Characteristics Page 11 Product Information Leaflet
Public Assessment Report. Decentralised Procedure. Tenofovir Zentiva 245 mg Film-coated Tablets. Tenofovir disoproxil fumarate UK/H/4970/001/DC
Public Assessment Report Decentralised Procedure Tenofovir Zentiva 245 mg Film-coated Tablets Tenofovir disoproxil fumarate UK licence no: PL 17780/0573 Winthrop Pharmaceuticals UK Limited 1 LAY SUMMARY
Public Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure Opticrom Allergy Single Dose 2% w/v Eye Drops, Solution (sodium cromoglicate) Procedure No: UK Licence No: PL 04425/0688 Aventis Pharma Limited (T/A Sanofi-aventis
Public Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure BOSENTAN ZENTIVA 62.5 MG FILM-COATED TABLETS BOSENTAN ZENTIVA 125 MG FILM-COATED TABLETS BOSENTAN ZENTIVA 62.5 MG FILM-COATED TABLETS BOSENTAN ZENTIVA 125
Hypromellose Eye Drops BP 0.3% w/v PL 23097/0006
Hypromellose Eye Drops BP 0.3% w/v PL 23097/0006 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 9 Summary of product characteristics Page 10 Patient
Arnicare Arnica 30c pillules NR 01175/0181 UKPAR
Arnicare Arnica 30c pillules NR 01175/0181 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Summary of product characteristics Page 12 Product
Public Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure Paracetamol 500 mg effervescent tablets Procedure No: UK/H/5662/001-002/DC UK Licence No: PL 36390/0177-0178 Cipla (EU) Limited Lay Summary Paracetamol
Public Assessment Report. Scientific discussion. Euplix 20 mg/20 drops (33.1 mg/ml) oral drops, solution. Paroxetine (as paroxetine mesilate)
Public Assessment Report Scientific discussion Euplix 20 mg/20 drops (33.1 mg/ml) oral drops, solution Paroxetine (as paroxetine mesilate) DK/H/0240/002/MR This module reflects the scientific discussion
Weleda Hayfever Relief Oromucosal Spray NR 00298/0275 UKPAR
Weleda Hayfever Relief Oromucosal Spray NR 00298/0275 UKPAR TABLE OF CONTENTS Lay summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 14 Summary of Product Characteristics Page
Public Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure IMATINIB TEVA UK 100 MG FILM-COATED TABLETS IMATINIB TEVA UK 400 MG FILM-COATED TABLETS (imatinib mesilate) Procedure No: UK Licence No: PL 00289/1516-1517
e-voke 10mg Electronic Inhaler PL 42601/0003 e-voke 15mg Electronic Inhaler PL 42601/0004 (Nicotine) UKPAR Nicovations Limited
e-voke 10mg Electronic Inhaler PL 42601/0003 e-voke 15mg Electronic Inhaler PL 42601/0004 (Nicotine) UKPAR Nicovations Limited 1 e-voke 10mg Electronic Inhaler PL 42601/0003 e-voke 15mg Electronic Inhaler
Public Assessment Report. Scientific discussion
Public Assessment Report Scientific discussion Dropodex 0.1% w/v eye drops, solution (Dexamethasone sodium phosphate) MT/H/0157/001/DC Date: 3 rd May, 2013 This module reflects the scientific discussion
DEXTROMETHORPHAN HYDROBROMIDE 10MG/5ML ORAL SOLUTION PL 17907/0314
DEXTROMETHORPHAN HYDROBROMIDE 10MG/5ML ORAL SOLUTION PL 17907/0314 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 10 Summary of Product Characteristics
Irish Medicines Board
Irish Medicines Board (Reference Member State) MUTUAL RECOGNITION PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT Clindaseptin 150 mg Capsules for Dogs CMD(v)/TEM/003-00
Public Assessment Report. Decentralised Procedure. Omega 3-acid-ethyl esters 1000mg Soft Capsules. Omega-3-acid ethyl esters 90
Public Assessment Report Decentralised Procedure Omega 3-acid-ethyl esters 1000mg Soft Capsules Omega-3-acid ethyl esters 90 Procedure No: UK Licence No: PL 00289/1756 and PL 00289/1778-80 Teva UK Limited
Public Assessment Report Scientific discussion. Hydrokortison CCS (hydrocortisone) SE/H/321/01/E01
Public Assessment Report Scientific discussion Hydrokortison CCS (hydrocortisone) SE/H/321/01/E01 This module reflects the scientific discussion for the approval of Hydrokortison CCS. The procedure was
Public Assessment Report Scientific discussion. Prednisolon Pilum (prednisolone) Asp no: 2013-0498
Public Assessment Report Scientific discussion Prednisolon Pilum (prednisolone) Asp no: 2013-0498 This module reflects the scientific discussion for the approval of Prednisolon Pilum. The procedure was
Public Assessment Report. Decentralised Procedure. Alimemazine tartrate 7.5mg/5ml Syrup. Alimemazine tartrate 30mg/5ml Syrup
Public Assessment Report Decentralised Procedure Alimemazine tartrate 7.5mg/5ml Syrup Alimemazine tartrate 30mg/5ml Syrup Procedure No: UK Licence No: PL 41830/0029-0030 NRIM Limited 1 LAY SUMMARY Alimemazine
Public Assessment Report. Scientific discussion. Ciclosporin Pharmachemie Capsules 25/50/100mg. (Ciclosporin)
Public Assessment Report Scientific discussion Ciclosporin Pharmachemie Capsules 25/50/100mg (Ciclosporin) PA holder Alpharma ApS This module reflects the scientific discussion for the approval of Ciclosporin
PUBLIC ASSESSMENT REPORT. Decentralised Procedure DE/H/2924/001/DC. Calcium 1000 mg / Vitamin D3 880 I.U. chewable tablets
Federal Institute for Drugs and Medical Devices PUBLIC ASSESSMENT REPORT Decentralised Procedure DE/H/2924/001/DC Calcium 1000 mg / Vitamin D3 880 I.U. chewable tablets Calcium carbonate, Cholecalciferol
Public Assessment Report
Public Assessment Report SoLo Prep PL 11847/0013 MHRA: PAR SoLo Prep PL 11847/0013 1 SOLO PREP PL 11847/0013 UKPAR TABLE OF CONTENTS Page Lay Summary 3 Scientific discussion 4 Steps taken for assessment
Public Assessment Report. Decentralised Procedure. PAR Flucloxacillin 250 mg & 500 mg Capsules. Flucloxacillin 500 mg Capsules.
Public Assessment Report Decentralised Procedure Flucloxacillin 250 mg Capsules Flucloxacillin 500 mg Capsules (flucloxacillin) Procedure No: UK/H/1101/001-002/DC UK Licence No: PL 21880/0017-0018 Medreich
Public Assessment Report. Decentralised Procedure
Public Assessment Report Decentralised Procedure Levodopa/Carbidopa/Entacapone Accord 100 mg/25 mg/200 mg Film-coated tablets Levodopa/Carbidopa/Entacapone Accord 150 mg/37.5 mg/200 mg Film-coated tablets